CC Chemours Co
Chemicals & Allied Products · NYSE · SEC CIK 1627223 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY56.0%
TTM EPS YoY56.2%
Revenue 3-yr CAGR-1.2%
Net income 3-yr CAGR—
Margins
Gross margin15.2%
Operating margin—
Net margin-2.6%
FCF margin3.6%
EBITDA margin—
Returns
ROE-71.8%
ROA-2.1%
ROIC (approx.)—
Asset turnover0.79x
Leverage & solvency
Liabilities / assets97.9%
Debt / equity24.73x
Current ratio1.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.60x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.81B | $5.78B | $6.08B | $6.83B | $6.34B |
| Cost of revenue | $4.91B | $4.64B | $4.78B | $5.21B | $4.96B |
| Gross profit | $902.00M | $1.14B | $1.30B | $1.62B | $1.38B |
| R&D expense | $108.00M | $109.00M | $108.00M | $118.00M | $107.00M |
| SG&A expense | $799.00M | $598.00M | $1.29B | $710.00M | $592.00M |
| Interest expense | $269.00M | $263.00M | $208.00M | $163.00M | $185.00M |
| Pretax income | -$277.00M | $106.00M | -$318.00M | $741.00M | $676.00M |
| Income tax | $109.00M | $37.00M | -$66.00M | $163.00M | $68.00M |
| Net income | -$386.00M | $69.00M | -$253.00M | $578.00M | $608.00M |
| EPS (basic) | -2.57 | 0.46 | -1.70 | 3.72 | 3.69 |
| EPS (diluted) | -2.57 | 0.46 | -1.70 | 3.65 | 3.60 |
| Dividends declared per share | 0.51 | 1.00 | 1.00 | 1.00 | 1.00 |
| Weighted avg. shares (diluted) | 150.24M | 150.17M | 148.91M | 158.30M | 168.70M |
| Balance sheet | |||||
| Cash & equivalents | $670.00M | $763.00M | $1.20B | $1.30B | $1.55B |
| Receivables | $562.00M | $619.00M | $622.00M | $509.00M | $644.00M |
| Inventory | $1.57B | $1.46B | $1.35B | $1.40B | $1.10B |
| Current assets | $3.00B | $3.02B | $3.84B | $3.21B | $3.35B |
| PP&E, net | $3.08B | $3.19B | $3.21B | $3.17B | $3.15B |
| Goodwill | $46.00M | $46.00M | $102.00M | $102.00M | $102.00M |
| Intangibles | $2.00M | $3.00M | $3.00M | $13.00M | $6.00M |
| Total assets | $7.38B | $7.51B | $8.24B | $7.64B | $7.55B |
| Current liabilities | $1.69B | $1.82B | $2.49B | $1.89B | $1.86B |
| Short-term debt | $42.00M | $54.00M | $51.00M | $43.00M | $25.00M |
| Long-term debt | $4.10B | $4.06B | $3.99B | $3.59B | $3.72B |
| Total debt | $4.14B | $4.11B | $4.04B | $3.63B | $3.75B |
| Total liabilities | $7.13B | $6.94B | $7.52B | $6.53B | $6.47B |
| Shareholders' equity | $250.00M | $571.00M | $721.00M | $1.11B | $1.08B |
| Net debt | $3.47B | $3.35B | $2.84B | $2.33B | $2.20B |
| Shares outstanding | 149.89M | 149.43M | 148.59M | 148.50M | 161.05M |
| Cash flow statement | |||||
| Operating cash flow | $264.00M | -$633.00M | $556.00M | $755.00M | $814.00M |
| Capital expenditure | $213.00M | $360.00M | $370.00M | $307.00M | $277.00M |
| Free cash flow | $51.00M | -$993.00M | $186.00M | $448.00M | $537.00M |
| Investing cash flow | -$206.00M | -$353.00M | -$229.00M | -$284.00M | $220.00M |
| Financing cash flow | -$126.00M | -$36.00M | $172.00M | -$686.00M | -$554.00M |
| Depreciation & amortization | $340.00M | $292.00M | $309.00M | $291.00M | $317.00M |
| Stock-based compensation | $21.00M | $15.00M | $18.00M | $27.00M | $34.00M |
| Dividends paid | $78.00M | $148.00M | $149.00M | $154.00M | $164.00M |
| Share buybacks | — | — | $69.00M | $495.00M | $173.00M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.